Abstract
Metabotropic glutamate (mGlu) and cannabinoid receptors are G-protein coupled receptors which have shown synaptic co-operation through small lipid messengers in the central nervous system (CNS). A functional interaction between these two receptor families could have a relevant potential in the treatment of CNS disorders, including chronic pain. Indeed, both mGlu and cannabinoid receptors play a crucial role in the neurobiology of pain and their simultaneous manipulation could lead to novel strategies in pain management. In particular, as both mGlu and cannabinoid receptors have been found in the periaqueductal gray (PAG), a crucial station in the pain modulatory system, these receptors could be a substrate for producing analgesia at this level. In this review we aim to briefly illustrate the role of mGlu and cannabinoid receptors in controlling nociceptive processes, some points of convergence, and their functional interaction in pain processing. Further insights into this functional linkage between the mGlu and cannabinoid receptors could pave the way to a new strategy for pain relief, such as a drug cocktail acting on cannabinoid/metabotropic glutamate receptors.
Keywords: Periaqueductal grey, metabotropic glutamate receptors, cannabinoid receptors, pain
Current Neuropharmacology
Title: Metabotropic Glutamate and Cannabinoid Receptor Crosstalk in Periaqueductal Grey Pain Processing
Volume: 4 Issue: 3
Author(s): E. Palazzo, V. de Novellis, I. Marabese, F. Rossi and S. Maione
Affiliation:
Keywords: Periaqueductal grey, metabotropic glutamate receptors, cannabinoid receptors, pain
Abstract: Metabotropic glutamate (mGlu) and cannabinoid receptors are G-protein coupled receptors which have shown synaptic co-operation through small lipid messengers in the central nervous system (CNS). A functional interaction between these two receptor families could have a relevant potential in the treatment of CNS disorders, including chronic pain. Indeed, both mGlu and cannabinoid receptors play a crucial role in the neurobiology of pain and their simultaneous manipulation could lead to novel strategies in pain management. In particular, as both mGlu and cannabinoid receptors have been found in the periaqueductal gray (PAG), a crucial station in the pain modulatory system, these receptors could be a substrate for producing analgesia at this level. In this review we aim to briefly illustrate the role of mGlu and cannabinoid receptors in controlling nociceptive processes, some points of convergence, and their functional interaction in pain processing. Further insights into this functional linkage between the mGlu and cannabinoid receptors could pave the way to a new strategy for pain relief, such as a drug cocktail acting on cannabinoid/metabotropic glutamate receptors.
Export Options
About this article
Cite this article as:
Palazzo E., de Novellis V., Marabese I., Rossi F. and Maione S., Metabotropic Glutamate and Cannabinoid Receptor Crosstalk in Periaqueductal Grey Pain Processing, Current Neuropharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157015906778019545
DOI https://dx.doi.org/10.2174/157015906778019545 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets What have Genetically Engineered Mice Taught Us About Ischemic Injury?
Current Molecular Medicine MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Pharmacokinetics and Metabolic Drug Interactions
Current Clinical Pharmacology Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Neurogenic Drugs and Compounds to Treat CNS Diseases and Disorders
Central Nervous System Agents in Medicinal Chemistry Cannabis Associated “High” Cardiovascular Morbidity and Mortality: Marijuana Smoke Like Tobacco Smoke? A Déjà Vu/Déjà Vécu Story?
Mini-Reviews in Medicinal Chemistry Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry Warfarin Dosing and the Promise of Pharmacogenomics
Current Clinical Pharmacology Antiviral Medication in Sexually Transmitted Diseases. Part III: Hepatitis B, Hepatitis C
Mini-Reviews in Medicinal Chemistry Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Clinical Profile of Mortality among Chronic Schizophrenic Patients: A Local Pilot Survey in Iran
Current Psychiatry Research and Reviews Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology